



Physician Order/Prescription & Statement of Medical Necessity



Please fax completed form to Chiesi Total CareSM staff at 866-272-7079

PATIENT INFORMATION

Patient Name (Last, First) _____
 Social Security # _____ - _____ - _____ Sex: Male Female Date of Birth ____/____/____ (mm/dd/yyyy)
 Address _____ City _____ State _____ Zip _____
 Primary Phone (Required) _____ Cell Phone _____ Language: English Other _____
 Parent/Guardian (If applicable) _____ Relationship to Patient _____

CLINICAL INFORMATION

Diagnosis: Adenosine deaminase severe combined immune deficiency (ADA-SCID) ICD-10 code D81.31 (primary)
 Secondary ICD-10 _____ Other ICD-10 _____
Treatment information
 Initial Rx for ADA-SCID Continuation on ERT Restart after Gene Therapy Restart after HSCT
 New patient/returning to therapy Other _____
 Height _____ inches or _____ cm Weight _____ lb or _____ kg Allergies: None Specify _____
 Known Drug Allergies: _____

INSURANCE INFORMATION

Primary Prescription Insurance _____	Primary Medical Insurance _____	Secondary Medical Insurance _____
Policy Holder _____	Policy Holder _____	Policy Holder _____
Policy ID # _____	Policy ID # _____	Policy ID # _____
Group # _____	Group # _____	Group # _____
Phone _____	Phone _____	Phone _____

Eligible for Medicare Eligible for Medicaid No Insurance

Please attach copies of patient insurance and prescription cards—front and back.

REVCovi (elapegademase-lvlr) PRESCRIPTION/ORDER

Revcovi (elapegademase-lvlr) 2.4 mg/1.5 mL single use vial NDC 10122-502-01 QTY _____ Refills _____
 Instructions: Inject _____ mg intramuscularly (IM) _____ times per week.
 Provide medical supplies, including syringes and needles, to safely administer prescribed medication.
 Skilled nursing visits _____ times for medication administration teaching

PRESCRIBER/OFFICE INFORMATION

Prescriber's Name (Print) _____ Practice/Group Name _____
 Address _____ Suite _____
 City _____ State _____ Zip _____
 Office Contact Person _____
 Office Phone _____ Office Fax _____
 License # _____ NPI # _____

By signing below, I certify that I am the prescribing provider mentioned above, that I am part of the Chiesi Total Care Program, that the therapy described above is medically necessary, and that all the medical necessity information is true, accurate, and complete. The patient's records contain supporting documentation that substantiates the utilization and medical necessity of the products marked above. I provide permission to use my personal information and the personal information of the patient provided above to facilitate this request and complete any regulatory or legal requirements associated with this request. I understand that the personal information provided herein may be shared with Chiesi, successors, and their agents and service providers as needed to support this request. I also attest that I have obtained the patient's authorization to release the above information and such other personal information as may be necessary for the Chiesi Total Care Program and/or their agents and service providers. If the patient is 18 years old or younger, I attest that I have obtained permission from the patient's legal guardian. I understand that any falsification, omission, or concealment of material fact may result in criminal liability.

Prescriber's Signature _____ Date _____
 Substitution Permitted _____ Dispense as Written _____

Revcovi is available as 2.4 mg/1.5 mL (1.6 mg/mL) intramuscular injection.

Questions? Chiesi Total Care is here to help! Please contact Chiesi Total Care at 866-272-7078 if you have questions regarding this form. Please see Important Safety Information on the reverse side.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

Please see [Full Prescribing Information](#) for more information.